Alberto Catalano

Summary

Affiliation: New South Wales
Country: Australia

Publications

  1. ncbi Molecular biology of lymphoma in the microarray era
    Alberto Catalano
    Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
    Pathology 37:508-22. 2005
  2. ncbi The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia
    Alberto Catalano
    Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia
    Blood 110:4073-6. 2007
  3. doi Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial
    Harry J Iland
    Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia University of Sydney, Sydney, NSW, Australia Electronic address
    Lancet Haematol 2:e357-66. 2015
  4. ncbi All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)
    Harry J Iland
    Royal Prince Alfred Hospital, Camperdown, Australia
    Blood 120:1570-80; quiz 1752. 2012
  5. pmc Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia
    Harry Iland
    Royal Prince Alfred Hospital, Camperdown, Australia
    Haematologica 97:227-34. 2012

Collaborators

  • Lynda J Campbell
  • Andrew Grigg
  • Mark A Dawson
  • Harry J Iland
  • Marnie Collins
  • Juliana Di Iulio
  • Kerry Taylor
  • Ken Bradstock
  • Mark Hertzberg
  • John Reynolds
  • Peter Browett
  • John F Seymour
  • Jeff Szer
  • John Taper
  • John Bashford
  • Michael Seldon
  • Robin Filshie
  • Frank Firkin
  • Campbell Tiley
  • Shane G Supple
  • John Moore
  • Amanda Hugman
  • Harry Iland
  • Paul Cannell
  • Sandra Deveridge
  • John Seymour
  • Shane Supple
  • Noemi Horvath
  • Li Chong
  • John Catalano
  • Tim Brighton
  • Juliet Ayling
  • Francisca Springall

Detail Information

Publications5

  1. ncbi Molecular biology of lymphoma in the microarray era
    Alberto Catalano
    Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
    Pathology 37:508-22. 2005
    ..Finally, a survey of the current trends in gene expression profiling of lymphomas by microarray technology will be presented with reference to implications for diagnosis, classification, prognosis and treatment...
  2. ncbi The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia
    Alberto Catalano
    Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia
    Blood 110:4073-6. 2007
    ..This trial was registered at www.actr.org.au with the Australian Clinical Trials Registry as number 12605000070639...
  3. doi Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial
    Harry J Iland
    Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia University of Sydney, Sydney, NSW, Australia Electronic address
    Lancet Haematol 2:e357-66. 2015
    ..To try to reduce the relapse rate, we combined arsenic trioxide with tretinoin and idarubicin in induction therapy, and used arsenic trioxide with tretinoin as consolidation therapy...
  4. ncbi All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)
    Harry J Iland
    Royal Prince Alfred Hospital, Camperdown, Australia
    Blood 120:1570-80; quiz 1752. 2012
    ..This trial was registered at the Australian New Zealand Clinical Trials Registry (www.anzctr.org.au) as ACTRN12605000070639...
  5. pmc Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia
    Harry Iland
    Royal Prince Alfred Hospital, Camperdown, Australia
    Haematologica 97:227-34. 2012
    ..The role of non-anthracycline drugs in induction and consolidation is less well-established and varies widely between different cooperative group protocols...